Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verrica PharmaceuticalsSTU:1NE0 -0.31%49 Gross Margin % is 82.30% as of Mar. 2026, which is 6% below its 10-year median of 87.89. GuruFocus rates STU:1NE0 with a GF Score™ of 49/100 and a GF Value™ of €15.51 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 733 Biotechnology companies, Verrica Pharmaceuticals ranks better than 84.17% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Verrica Pharmaceuticals had a gross margin of 82.30% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Verrica Pharmaceuticals Gross Margin % Related Terms
Verrica Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:1NE0 vs ENGN, PEPG, ONCY: Gross Margin % Comparison
For the Biotechnology subindustry, Verrica Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verrica Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Verrica Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Verrica Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Verrica Pharmaceuticals (STU:1NE0) has a Gross Margin % of 82.30% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Verrica Pharmaceuticals and its competitors. This is near median its historical median of 87.89. Over the past decade, Verrica Pharmaceuticals' Gross Margin % has ranged from 63.79 to 91.97. According to the industry distribution chart, Verrica Pharmaceuticals ranks #116 out of 733 companies in the Biotechnology industry, placing it in the top 15.8%.
Is Verrica Pharmaceuticals' Gross Margin % too high?
Verrica Pharmaceuticals' current Gross Margin % of 82.30% is near median its 10-year median of 87.89. Over the past 10 years, this metric has ranged from a low of 63.79 to a high of 91.97. The Biotechnology industry median Gross Margin % is 60.91. Verrica Pharmaceuticals' value of 82.30% is 35.1% above this industry median. Based on the distribution chart, Verrica Pharmaceuticals ranks #116 out of 733 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Verrica Pharmaceuticals has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Verrica Pharmaceuticals' Gross Margin % compare to ENGN and PEPG?
According to the Biotechnology industry distribution chart, Verrica Pharmaceuticals ranks #116 out of 733 companies for Gross Margin %. This places Verrica Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Verrica Pharmaceuticals' value of 82.30% is 35.1% above this benchmark. Historically, Verrica Pharmaceuticals' own Gross Margin % has ranged from 63.79 to 91.97 over the past decade. While the company's 10-year median is 87.89 vs. the industry median of 60.91, Verrica Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verrica Pharmaceuticals's current Gross Margin % of 82.30% is 35.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Verrica Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verrica Pharmaceuticals's current Gross Margin % is 82.30%, which is near median its own 10-year median of 87.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verrica Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Verrica Pharmaceuticals (STU:1NE0) is currently considered Possible Value Trap. The stock's GF Value™ is €15.51, compared to a current price of €4.86 — trading 68.7% below its estimated fair value. The current Gross Margin % is 82.30%, which is near median its 10-year median of 87.89 and 35.1% above the Biotechnology industry median of 60.91. Verrica Pharmaceuticals' overall GF Score™ is 49/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Verrica Pharmaceuticals (STU:1NE0), the current Gross Margin % is 82.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Verrica Pharmaceuticals (STU:1NE0) Overvalued in 2026?
Based on GuruFocus' analysis, Verrica Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.86 is trading 68.7% below its estimated GF Value™ of €15.51.
GuruFocus considers Verrica Pharmaceuticals to be Possible Value Trap.
Key valuation signals for STU:1NE0:
Gross Margin %: 82.30% (near median its 10-year median of 87.89)
GF Value™: €15.51 vs. price of €4.86 (68.7% below fair value)
Industry Position: 35.1% above the Biotechnology median (#116 of 733)
No single metric tells the full story. See the STU:1NE0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
49GF Score
Get the complete analysis for STU:1NE0
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:1NE0 has been successfully added to your 
